 NOTE: Patients in group 1 begin delayed ADT at least 2 years after study entry unless 1 of the following clinical criteria is present: prostate-specific antigen PSA doubling time of 12 months with PSA 10 ngmL OR PSA doubling time of 6 months based on 3 consecutive measurements obtained 2 months apart OR development of metastases or symptoms. Patients in group 2 begin delayed ADT at least 2 years after study entry unless 1 of the following clinical criteria is present: development of symptoms OR PSA 60 ngmL OR PSA doubling time of 6 months based on 3 consecutive measurements obtained 2 months apart. 